StockIQpro
NASDAQ:BJDX

Bluejay Diagnostics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Bluejay Diagnostics, Inc. reported net income of −$6.8M in fiscal 2025. Free cash flow was −$6.2M, and the diluted share count rose 879.4%.Summary generated from Bluejay Diagnostics, Inc.'s SEC filings. Latest annual report filed Mar 6, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−117.0%
Debt / equityn/a
Free cash flow−$6.2M
FCF marginn/a
Share count change+879.4%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/a0n/an/an/a
Operating income−3−9−10−7−7
Net income−3−9−10−8−7
Free cash flow−4−9−9−8−6

Recent filings

From SEC EDGAR

Peers

Surgical & medical instruments & apparatus